24/7QualityMeds, Author at 24/7 QualityMeds

November 3, 2025

Mirvetuximab soravtansine-gynx for the treatment of adult patients with FRα–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. Patients are selected for therapy based on an FDA-approved test.

Mirvetuximab soravtansine-gynx is an antibody-drug conjugate (ADC) where the monoclonal antibody is a chimeric IgG1 that targets folate receptor alpha (FRα). Th antibody is linked to a small molecule, DM4 (also known as soravtansine or ravtansine), a microtubule inhibitor by a cleavable linker. Upon binding to FRα, mirvetuximab soravtansine-gynx is internalized followed by intracellular release of DM4 via proteolytic cleavage. DM4 disrupts the microtubule network within the cell, resulting in cell cycle arrest and apoptotic cell death, and diffuse to nearby cells causing further cell death. FRα is a receptor that is overexpressen on the surface epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast and non-small-cell lung cancers.

The most common adverse reactions include vision impairment, pneumonitis, fatigue, increased aspartate aminotransferase, nausea, increased alanine aminotransferase, keratopathy, abdominal pain, decreased lymphocytes, peripheral neuropathy, diarrhea, decreased albumin, constipation, increased alkaline phosphatase, dry eye, decreased magnesium, decreased leukocytes, decreased neutrophils, and decreased hemoglobin.

The cytotoxic and gentoxic component DM4 can be toxic to actively dividing cells, suggesting its potential to cause embryotoxicity and teratogenicity. Advise patients of potential risk to fetus.

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment and for 1 month after the last dose.

Advise females to use effective contraception during treatment and for 7 months after the last dose.

Safety and effectiveness of mirvetuximab have not been established in pediatric patients.

No clinically meaningful differences in efficacy or safety were observed in geriatric patients compared to younger patients. No dosage adjustment of mirvetuximab is recommended for patients with mild to moderate renal or mild hepatic impairment. The effect of severe renal impairment or end-stage renal disease on mirvetuximab is unknown. Avoid use of mirvetuximab in patients with moderate or severe hepatic impairment.

Pricing and Availability

Mirvetuximab Soravtansine (Elahere) is not registered in India and, therefore, not easily available through local pharmacies or standard supply channels.
As this is a prescription-only treatment, the price quotation for mirvetuximab is shared on request, after submission of valid medical documents. For the most current pricing and procurement details, patients or caregivers can contact us directly.

The cost of mirvetuximab in India may differ depending on market trends, supplier access, and regulatory developments, since the medicine is not approved for commercial distribution in the country. The overall price also varies based on supplier, country of origin, shipping costs, and documentation requirements.

Prices may further fluctuate due to GST/local taxes, currency exchange rates, and changes in manufacturer pricing policies. We assist patients in importing mirvetuximab in India safely and lawfully, ensuring complete compliance with the Named Patient Supply (NPS) program. Our team supports patients through each step-from verifying documents to final delivery.

Access

As mirvetuximab is not commercially approved in India, it can only be accessed through the Named Patient Import Program (NPIP). We support patients requiring medicines by helping procure them under the Named Patient Supply (NPS) route.

Each mirvetuximab soravtansine-gynx injection carton contains one single-dose vial containing 100 mg of mirvetuximab soravtansine-gynx in 20 mL (5 mg/mL) of clear to slightly opalescent, colorless sterile solution.

Import Process

Submit a request for your medicine
Patients or caregivers can share their prescription and treatment details to initiate the request.
Apply through Form 12A
An application in Form 12A must be submitted along with a valid prescription from a Registered Medical Practitioner (RMP).
Document verification
All medical documents and prescriptions are verified to confirm eligibility for importing the medicine in small quantities for personal medical use.
Import permission
Once approval is granted by the Drugs Controller General (India), the import procedure begins as per the prescription.
Sourcing the medicine
Our sourcing team coordinates with authorized international suppliers to find the best available price of mirvetuximab soravtansine in India, ensuring product authenticity before finalizing the purchase.
Medicine delivery
After approval and confirmation, logistics are coordinated to ensure safe, compliant, and timely delivery to the patient’s address in India.

Required Documents

To enable the import of mirvetuximab to India, patients must provide:

A valid prescription specifying the medicine name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming the diagnosis.
Government-issued ID and proof of residence of the patient.
Import permit (if applicable).

The order is confirmed only after receiving a valid prescription and the required documents. Once the import permit is approved, the licensed supplier arranges shipment of mirvetuximab from approved international sources such as the USA, Canada, Europe, or Australia.

Through this process, patients can import mirvetuximab into India safely and legally. We make the medicine available across major cities, sourcing only from genuine international suppliers to ensure quality and authenticity. We maintain complete transparency in pricing, and all prescriptions are reviewed by registered pharmacists before final dispatch. For pricing details or to request assistance in accessing mirvetuximab, visit 24/7QualityMeds.com.

by 24/7QualityMeds

November 1, 2025

Foscavir is the brand name for foscarnet sodium. Foscarnet exerts its antiviral activity by a selectively inhibiting the pyrophosphate binding site on virus-specific DNA polymerases at concentrations that do not affect cellular DNA polymerases. It does not require activation by thymidine kinase or other kinases.

Foscarnet is indicated for the treatment of:

CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). The combination of foscarnet and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. Safety and efficacy of foscavir have not been established for treatment of other CMV infections (e.g., pneumonitis, gastroenteritis); congenital or neonatal CMV disease; or nonimmunocompromised individuals.
Acyclovir-resistant mucocutaneous hsv infections in immunocompromised patients. Safety and efficacy of foscarnet have not been established for treatment of other HSV infections (e.g., retinitis, encephalitis); congenital or neonatal HSV disease; or HSV in nonimmunocompromised individuals.

Adverse reactions of this medicine primarily include renal impairment, mineral and electrolyte abnormalities, seizures, hypersensitivity, QT prolongation. Insufficient well-controlled studies of foscavir is not done in pregnant women. There is potential for serious adverse events in nursing infants, and hence a decision should be made considering the importance of the drug to the mother. The safety and effectiveness of foscavir in pediatric patients have not been established. Since deposition in human bone has also been shown to occur, it is likely that it does so to a greater degree in developing bone in pediatric patients. No studies regarding efficacy or safety of foscavir in geriatric patients, however consistent patterns in adverse reactions seen across all age groups. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Elderly patients are at higher chance of having impaired renal function, care should be taken in dose selection, with monitoring of renal function.

Pricing and availability:

Foscarnet is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for Foscavir is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us.

The price of foscarnet in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy foscarnet India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As foscarnet is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like foscarnet in India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Foscavir or foscarnet (foscarnet sodium) injection, 24 mg/mL, for intravenous infusion, is supplied in 250 mL glass bottles containing 6000 mg foscarnet sodium (24 mg/mL) as 250 mL bottles, or in cases of 10.

Import process:

Request submission for your medicine
Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A)
Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents
We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import
Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine
Our sourcing team connects with authorized global suppliers to find the best foscarnet price in India, thus making it convenient to easily import foscarnet in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine
After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Foscavir from the USA, Canada, Europe, or Australia etc.

With these steps, patients can import Foscarnet in India safely and legally. We ensure availability across major Indian cities and source only from verified international suppliers to maintain product authenticity and quality. Pricing is fully transparent, and all prescriptions are verified by registered pharmacists before delivery. For assistance with pricing, documentation, or procurement, patients may contact 24/7QualityMeds.com for reliable support and seamless access.

by 24/7QualityMeds

October 30, 2025

Sotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen. It is indicated in the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) witj the KRAS-G12C mutation in adults who have received at least one prior systemic therapy. It is additionally approved in combination with panitumumab for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluorouracil-, oxaliplatin– and irinotecan-based chemotherapy.

The usual pathway consists of GTP binding to KRAS, aloowing downstream signalling through MAP kinase pathway. GTP is hydrolyzed to GDP, and KRAS is inactivated. KRAS G12C mutations impair hydrolysis of GTP, leaving it in the active form. Sotorasib, being a KRASG12C inhibitor, binds to the cysteine residue in KRAS G12C mutations, holding the protein in its inactive form. The cysteine residue that sotorasib targets is not present in the wild type KRAS, which prevents off-target effects. This mutation is present in 13% of non-small cell lung cancer, 3% of colorectal and appendix cancer, and 1-3% of solid tumors. This enables blocking and KRAS signaling, inhibited cell growth, and promoted apoptosis specifically in KRAS G12C tumor cell lines. This product has inhibited KRASG12C in vitro and in vivo with minimal detectable off-target activity. In mouse tumor xenograft models, sotorasib treatment led to tumor regressions and prolonged survival, and was associated with anti-tumor immunity in KRAS G12C models.

There are no available data on Sotorasib use in pregnant women. Because of the potential for serious adverse reactions in breastfed children, women are advised not to breastfeed during treatment with Lumakras and for 1 week after the final dose. The safety and effectiveness of this product have not been established in pediatric patients. No overall differences in safety or effectiveness were observed between older patients and younger patients. No dosage modification is recommended in patients with mild to moderate hepatic impairment (Child Pugh A or B). The effect of severe hepatic impairment (Child-Pugh C) on the safety of LUMAKRAS is unknown. Monitor for sotorasib adverse reactions in patients with hepatic impairment more frequently since these patients may be at increased risk for adverse reactions including hepatotoxici

Pricing and availability:

Sotorasib is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for sotorasib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us.

The price of sotorasib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy sotorasib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As sotorasib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like sotorasib in India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Sotorasib or Lumakras is available as 320 mg tablets in carton containing one bottle of 90 tablets with child-resistant closure and as 120 mg tablets in carton containing two bottles of 120 tablets or one bottle of 240 tablets with child-resistant closure,

Import process:

Request submission for your medicine
Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A)
Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents
We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import
Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine
Our sourcing team connects with authorized global suppliers to find the best sotorasib price in India, thus making it convenient to easily access Lumakras in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine
After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Lumakras from the USA, Canada, Europe, or Australia, etc.
With these steps, patients can import sotorasib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

If you are exploring reliable options to buy Sotorasib (Lumakras) in India, expert assistance is available. For accurate pricing, availability updates, and end-to-end support with the import process, you may reach out to 24/7QualityMeds. Their team helps ensure compliant sourcing and smooth delivery so patients can access this essential therapy with confidence.

by 24/7QualityMeds

October 29, 2025

Mitotane is indicated in the treatment of inoperable adrenal cortical carcinoma of both functional and nonfunctional types. Mitotane or Lysodren is an adrenal cytotoxic agent which can cause adrenal inhibition, apparently without cellular destruction. The exact biochemical mechanism of action is unknown. Available data suggest that the drug modifies the peripheral metabolism of steroids as well as suppresses the adrenal cortex. It ultimately leads to reduced production of adrenal corticosteroids and aids in accumulation of free cholesterol toxic to adrenal cells.

Adverse reactions include gastrointestinal disturbances like anorexia, nausea or vomiting, and diarrhea; central nervous system side effects, primarily depression as manifested by lethargy and somnolence, dizziness or vertigo; skin toxicity, et cetera. Infrequently occurring side effects involve the eye, the genitourinary, cardiovascular system; and generalized aching, hyperpyrexia, and lowered protein bound iodine.

Mitotane or Lysodren is usually present in breast- milk. Hence, women are advised not to breastfeed during treatment. Safety and effectiveness in pediatric and geriatric patients has not been established sufficiently. In few clinical studies performed with geriatric patients, no significant differences in adverse reaction occurrence. However, dose adjustments are required in consideration with the co-occurence of hepatic, renal, cardiac impairment as well as any other drug or treatment being used.

Pricing and availability:

Mitotane is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for mitotane is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us.

The price of mitotane in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy mitotane (Lysodren) in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As mitotane is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like encorafenib in India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Mitotane or Lysodren is available as 500 mg tablets, 100 in each bottle.

Import process:

Request submission for your medicine
Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A)
Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents
We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import
Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine
Our sourcing team connects with authorized global suppliers to find the best mitotane price in India, thus making it convenient to easily import mitotane in India and ensure authenticity before finalizing the offer.
Delivery of the medicine
After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming the disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Lysodren from the USA, Canada, Europe, or Australia, etc.

With these steps, patients can import Mitotane in India safely and legally. We source only from verified international suppliers to ensure authenticity and make the medicine available across major Indian cities. Every order is handled with 100% transparency, and Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

For guidance on pricing, availability, and compliant import support for Mitotane, you can connect with 24/7QualityMeds for seamless assistance.

by 24/7QualityMeds

October 28, 2025

Braftovi or encorafenib is a prescription medication used to treat certain cancers that have spread (metastasized), cannot be removed with surgery, and have specific mutations in the BRAF gene. It is used in to treat (a) Melanoma and Non-Small Cell Lung Cancer (NSCLC): In combination with Mektovi (binimetinib), encorafenib is used to treat adults with melanoma or NSCLC that has a BRAF mutation. (b) Colorectal Cancer (CRC): In combination with cetuximab and mFOLFOX6 (a chemotherapy regimen including fluorouracil, leucovorin, and oxaliplatin) to treat colorectal cancer.

The approval for this combination was based on response of the tumour and its duration. Ongoing studies are evaluating the clinical benefit of this regimen.
Encorafenib may also be used in combination with cetuximab alone for adults with colorectal cancer who have previously received treatment.
Encorafenib is advised against for the treatment of people whose melanoma, colorectal cancer, or NSCLC has wild-type BRAF (no BRAF mutation), due to insufficient studies. Your healthcare provider will perform a test to confirm if encorafenib or the combination with binimetinib is appropriate for your condition.

Encorafenib is a BRAF kinase inhibitor targeting mutated BRAF – BRAF V600E, wild-type BRAF, and CRAF, inhibiting tumor growth via the suppression of RAF/MEK/ERK pathway. It also binds other kinases at clinically relevant levels. In combination with binimetinib or cetuximab, it showed better anti-tumor effects and delayed resistance in BRAF-mutant models. Resistance in BRAF-mutant CRC due to EGFR activation can be overcome with EGFR-targeted combination therapy.

New primary malignancies, hemorrhage, uveitis and QT prolongation are the common side effects of encorafenib treatment. Breastfeeding is not recommended during treatment and for 2 weeks after. Encorafenib may impact and impair male fertility and reduce any effectiveness of hormonal contraceptives. Therefore, non-hormonal contraception is advised. Effective contraception used during and for 2 weeks after therapy.

In clinical trials, no significant effect of the product’s safety or effectiveness were seen in elderly patients. However, it is NOT approved for pediatric use. No dose adjustment is needed for mild to moderate renal or hepatic impairment, and use in severe impairment lacks dosing recommendations.

Pricing and availability:

Encorafenib (Braftovi) is a targeted therapy designed for adults with melanoma, NSCLC, and colorectal cancer with a BRAF mutation that have spread or cannot be surgically removed. It aids in improving tumor response and the duration of benefit. When used in combination with binimetinib or cetuximab-based regimens, it offers a powerful, personalized treatment. It is not suitable for cancers without the BRAF mutation.

However, encorafenib is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for encorafenib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us.

The price of encorafenib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy encorafenib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As encorafenib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like encorafenib in India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Braftovi or encorafenib is supplied as 75 mg capsules available in cartons containing two bottles of 90 capsules each and cartons containing two bottles of 60 capsules each.

Import process:

Request submission for your medicine
Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A)
Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents
We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import
Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine
Our sourcing team connects with authorized global suppliers to find the best encorafenib price in India, thus making it convenient to easily import encorafenib in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine
After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Braftovi from the USA, Canada, Europe, or Australia, etc.
With these steps, patients can import encorafenib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

Accessing Encorafenib (Braftovi) in India can be made seamless and compliant through the Named Patient Supply (NPS) Program. With proper guidance, patients can obtain this essential therapy safely and legally under the supervision of qualified healthcare professionals.

At 24/7 QualityMeds, we assist patients and caregivers through every stage—from documentation and regulatory approvals to sourcing from verified international suppliers. Our focus is on ensuring genuine medicines, transparent pricing, and reliable delivery across India. For the most updated details on Encorafenib pricing, availability, and import assistance in India, please contact our expert support team.

by 24/7QualityMeds

October 25, 2025

Tukysa is a HER2-directed tyrosine kinase inhibitor approved in combination therapy that has demonstrated a significant overall survival benefit in patients with HER2-positive metastatic breast cancer—including those with brain metastases. Its ability to cross the blood-brain barrier and maintain efficacy makes it a critical advancement in treatment of HER2+ disease. Its favorable tolerability profile, and ability to be used post multiple HER2-targeted therapies make it a valuable option in the treatment landscape for HER2-positive metastatic breast cancer.

This product manufactured by Seagen (Seattle Genetics) is a HER2-directed kinase inhibitor, meaning it blocks HER2 and HER3 phosphorylation in vitro, inhibiting downstream MAPK and AKT signaling, and reducing cell proliferation. It has shown anti-tumor activity in HER2-expressing cells. In vivo, tucatinib inhibited HER2-positive tumor growth. When combined with trastuzumab, tucatinib demonstrated enhanced anti-tumor effects in both in vitro and in vivo models compared to either agent alone.

Recommended dosage is 300 mg, orally, twice daily with or without food; and for patients with severe hepatic impairment is 200 mg orally twice daily.

Some of the clinically significant adverse reactions include diarrhea, embryo fetal toxicity and hepatotoxicity.

Pricing and availability:

Tucatinib (Tukysa) is prescribed for patients with HER2- positive metastatic breast cancer. However, tucatinib is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for tucatinib is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us.

The price of tucatinib in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy tucatinib India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As tucatinib is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients with products like tucatinib in India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Tukysa or tucatinib is supplied as 50 mg or 150 mg tablets with 60 counts in each of 75 cc bottles or 150 mg tablets as 120 counts in each of 150 cc bottles.

Import process:

Request submission for your medicine
Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A)
Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents
We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import
Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine
Our sourcing team connects with authorized global suppliers to find the best anakinra price in India, thus making it convenient to easily import tucatinib in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine
After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Tukysa from the USA, Canada, Europe, or Australia, etc.
With these steps, patients can import tucatinib India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

by 24/7QualityMeds

October 17, 2025

Kineret, also known by its generic name Anakinra, is a biologic prescription medicine that belongs to the class of interleukin-1 receptor antagonists (IL-1Ra), produced by recombinant DNA technology. It works by blocking the activity of interleukin-1 (IL-1), a protein involved in inflammation. By reducing IL-1 activity, it helps control symptoms and progression of several rare and severe inflammatory diseases.

Kineret is approved for treating:

Rheumatoid Arthritis (RA) in adults who have not responded to one or more other treatments.
Neonatal-Onset Multisystem Inflammatory Disease (NOMID): A rare form of Cryopyrin-Associated Periodic Syndromes (CAPS).
Deficiency of Interleukin-1 Receptor Antagonist (DIRA): A life-threatening genetic condition

Adverse reactions can include infections in upper respiraotory tract, injection site reaction, worsening of rheumatoid arthritis,, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain in RA patients; injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis in NOMID patients; upper respiratory tract infections, rash, pyrexia, influenza like illness, and gastroenteritis in DIRA patients. Higher risk of adverse reactions and their severity in geriatric patients and those with renal impairment. Refer label for detailed drug information.

Anakinra (Kineret) is a vital biologic therapy for patients with Rheumatoid Arthritis, NOMID, and DIRA, offering significant improvements in health outcomes and, in some cases, survival. While the Kineret price in India can vary, legal import channels ensure transparency and access to genuine medicine.

Pricing and availability:

Anakinra is prescribed for patients requiring treatment of rheumatoid arthritis, NOMID and DIRA. However, ankainnra is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for anakinra is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us.

The price of anakinra (Kineret) in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy anakinra India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As Anakinra is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients to products like Kineret in India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Anakinra or Kineret is supplied in 100 mg/0.67 mL prefilled syringes (packs of 28 injections),

Import process:

Request submission for your medicine
Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A)
Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents
We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import
Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine
Our sourcing team connects with authorized global suppliers to find the best anakinra price in India, confirm easy import of anakinra in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine
After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

Order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Kineret from the USA, Canada, Europe, or Australia, etc.
With these steps, patients can import anakinra in India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

by 24/7QualityMeds

October 15, 2025

Blinatumomab belongs to the group of chemotherapeutic drugs “BiTES” or bispecific T-cell engagers. Blinatumomab is particularly directed to CD19 on B cells and CD3 on T-cells. This antibody based therapy is produced in CHO cell lines or Chinese hamster ovary cells.

Blinatumomab engages and activates endogenous T-cells as it is particularly directed to CD19 on benign and malignant B cells and CD3in TCR complex on T-cells. This allows formation of a synapse between the T-cell and the tumor cell, thus upregulating cell adhesion molecules, production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T-cells, ultimately resulting in lysis of CD19+ cells.

Blinatumomab is indicated for the treatment of aadults and pediatric patients one month or older with the following:

CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% .
Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL).
CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy.

Some of the adverse reactions associated with blinatumomab use include cytokine release syndrome, neurological toxicities, including ICANS (immune effector cell-associated neurotoxicity syndrome), infections, tumor lysis syndrome, neutropenia and febrile neutropenia, effects on ability to drive and use machines, elevated liver enzymes, pancreatitis, leukoencephalopathy

Pricing and availability:

Blincyto 38.5 mcg Injection in India is usually prescribed by hematologists and oncologists, especially for patients who are candidates for bone marrow transplant (BMT). However, Blincyto is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Since this is a prescription-only therapy, the price quotation for blinatumomab is provided upon request, after submission of valid medical documents. For updated pricing and procurement details, contact us.

The price of Blincyto (blinatumomab) in India may vary depending on market dynamics, supplier availability, and regulatory updates, since the drug is not registered for commercial sale in India. Cost also depends on supplier, origin country, shipping and documentation. For the most accurate and updated pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy blinatumomab in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

As blinatumomab is not commercially registered in India, it can only be accessed through the Named Patient Import Program (NPIP). We assist patients in the import of blinatumomab India by procuring medicines for patients under the Named Patient Supply (NPS) route.

Each Blincyto package contains: One blinatumomab for injection 35 mcg single-dose vial and one IV Solution Stabilizer 10 mL single-dose glass vial. It is administered as an intravenous injection and the dose is as follows:

Day 1-28:
- 28 mcg/day for weight > 45 kg
- 15 mcg/day for weight < 45 kg.
Day 29-42:
- 14-day treatment interval

Import process:

Request submission for your medicine
Patients or caregivers can send a request for the product by sharing prescription details and treatment requirements.
Submission of an application (Form 12A)
Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents
We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import
Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine
Our sourcing team connects with authorized global suppliers to find the best blincyto price in India, confirm easy import blinatumomab in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine
After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of the product to the patient’s location in India.

Documents Require:

To enable the product’s import to India, patients need to provide:

A valid doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months), including those confirming the disease.
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

The order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Blincyto from the USA, Canada, Europe, or Australia etc.
With these steps, patients can import blinatumomab in India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing, and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before being delivered to patients.

by 24/7QualityMeds

October 13, 2025

Trodelvy® (brand name by Gilead sciences)(sacituzumab govitecan-hziy) is a Trop-2-directed antibody-drug conjugate used to treat metastatic triple-negative and HR+/HER2- breast cancers in adults who have received prior therapies. It delivers SN-38, a topoisomerase-1 inhibitor, to Trop-2-expressing tumor cells, blocking DNA replication and causing cell death.

Mode of action of sacituzumab govitecan-hziy is mainly that it delivers SN-38, a topoisomerase-1 inhibitor, to Trop-2-expressing cancer cells. It treats adults with metastatic triple-negative breast cancer (TNBC) after two or more prior therapies, and HR+/HER2- metastatic breast cancer after endocrine and systemic therapies. It’s also used for locally advanced or metastatic urothelial cancer post-platinum and PD-1/PD-L1 inhibitor treatment.

Neutropenia, diarrhea, hypersensitivity and infusion-related reactions, nausea and vomiting are the common side effects. Trodelvy may have teratogenic effects and can cause embryo-fetal lethality when administered during pregnancy.

Trodelvy promises to help in overall survival of metastatic cancer which is difficult to treat with other therapies, and being a targeted therapy, it allows precise delivery of drugs and an increased chances of survival with less or no progression.

Pricing and Availability

The price of sacituzumab govitecan-hziy in India may vary depending on market dynamics, supplier availability, and regulatory updates. For the most accurate and updated sacituzumab govitecan-hziy pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy sacituzumab govitecan in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Access:

We assist patients and hospitals in legally importing for personal medical use and provide reliable access across major Indian cities. Sacituzumab govitecan-hziy is a prescription drug available as 180 mg lyophilized powder in single-dose vials for reconstitution, for injection. and requires a valid medical prescription from a qualified doctor. It can be imported under the Named Patient Supply (NPS) program, which allows patients to access unapproved or unavailable medicines in India for personal treatment use.

Access Process:

Request submission for your medicine: Patients or caregivers can send a request for sacituzumab govitecan-hziy by sharing prescription details and treatment requirements.
Submission of an application (Form 12A): Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents: We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import: Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine: Our sourcing team connects with authorized global suppliers to find the best sacituzumab govitecan-hziy or trodelvy price in India, confirm easy access trodelvy in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine: After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of sacituzumab govitecan-hziy to the patient’s location in India.

Documents Require:

To enable sacituzumab import to India, patients need to provide:

A doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months).
Government-issued ID proof and proof of residence of the patient.
Import permit if applicable.

The order is finalized only after submission of a valid prescription and necessary documents. Once the import permit is approved, the licensed supplier arranges shipment of Trodelvy from the USA, Canada, Europe, or Australia, etc.

With these steps, patients can import sacitizumab-govitecan India safely and legally. We make the medicines available in major Indian cities and source only from genuine international suppliers to ensure safety and authenticity. We ensure 100% transparency in pricing and supply is guaranteed. Prescriptions are dispensed and checked by registered pharmacists before delivery to patients.

by 24/7QualityMeds

October 10, 2025

Foscarnet is an antiviral drug primarily used to treat cytomegalovirus (CMV) associated retinitis in patients with AIDS and acyclovir-resistant herpes simplex virus (HSV) infections in immunocompromised individuals. It is especially essential when standard antiviral treatments such as acyclovir or ganciclovir fail due to viral resistance.

Foscarnet does not require activation by viral enzymes, unlike other antiviral agents. It acts by blocking the pyrophosphate-binding site of viral DNA polymerase, inhibiting viral DNA synthesis without affecting normal cellular DNA polymerases. This unique, non-nucleoside pyrophosphate analog mechanism gives Foscarnet potent activity against herpesviruses, including CMV, HSV, and varicella-zoster virus (off label treatment) and HIV.

Clinically, Foscarnet is FDA-approved for treating CMV retinitis in patients with AIDS who cannot tolerate or have failed ganciclovir therapy, and as a salvage therapy in resistant CMV infections and for mucocutaneous HSV infections unresponsive to acyclovir in immunocompromised patients.

Foscarnet’s key advantage lies in its distinct mechanism of action, making it effective against drug-resistant herpesvirus strains. This makes it the drug of choice for managing severe, resistant CMV and HSV infections in vulnerable, immunocompromised patients.

Access:

We assist patients and hospitals in legally importing Foscranet for personal medical use and provide reliable access across major Indian cities.

Foscarnet is a prescription drug available as 250 mL glass bottles containing 6000 mg foscarnet sodium (24 mg/mL) for single use vial and requires a valid medical prescription from a qualified doctor. It can be imported under the Named Patient Supply (NPS) program, which allows patients to access unapproved or unavailable medicines in India for personal treatment use.

Access Process:

Send a request for your medicine: Patients or caregivers can send a request for Foscarnet by sharing prescription details and treatment requirements.
Submission of an application (Form 12A): Submit an application in Form 12A, along with a valid prescription from a Registered Medical Practitioner (RMP).
Verification of documents: We verify the prescription and supporting medical documents to confirm eligibility for importing the drug in small quantities for personal medical use.
Permission to import: Once approval is granted by the Drugs Controller General (India), the process of importing medicines begins as per the prescription.
Sourcing the medicine: Our sourcing team connects with authorized global suppliers to find the best foscarnet price in India, confirm Foscarnet availability in India, and ensure authenticity before finalizing the offer.
Delivery of the medicine: After approval and confirmation, we coordinate logistics and ensure the safe, compliant, and timely delivery of Foscarnet to the patient’s location in India.

Documents Required:

To import Foscarnet into India, patients need to provide:

A doctor’s prescription specifying the product name, dosage, treatment duration, and diagnosis.
Recent medical history and test reports (preferably from the last three months).
Government-issued ID proof and proof of residence of the patient.

Pricing and Availability:

The price of Foscarnet in India may vary depending on market dynamics, supplier availability, and regulatory updates. For the most accurate and updated Foscarnet pricing in India, patients can contact us directly.
Pricing may also fluctuate due to GST/local taxes, exchange rates, and changes in company pricing policies.

We help patients buy foscarnet in India safely and legally, ensuring full regulatory compliance under the Named Patient Supply (NPS) program and providing assistance throughout the process—from document verification to final delivery.

Newer Posts

Older Posts